Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Bioniz	Registered Direct Offerings	Common Stock	Common Stock Bioniz	Common Stock Registered Direct Offerings	Additional Paid-in Capital	Additional Paid-in Capital Bioniz	Additional Paid-in Capital Registered Direct Offerings	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2020	$ 69,854			$ 2			$ 141,074			$ (297)	$ (70,925)
Balance, Shares at Dec. 31, 2020				24,753,102
Issuance of common stock under registered direct offering, net of offering costs			$ 29,909						$ 29,909
Issuance of common stock under registered direct offering, net of offering costs, Shares						4,285,710
Exercise of stock options	4						4
Exercise of stock options, Shares				1,458
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,044						1,044
Other comprehensive income (loss)	42									42
Net loss	(8,991)										(8,991)
Balance at Mar. 31, 2021	91,880			$ 2			172,049			(255)	(79,916)
Balance, Shares at Mar. 31, 2021				29,040,270
Balance at Dec. 31, 2021	66,505			$ 2			176,618			(138)	(109,977)
Balance, Shares at Dec. 31, 2021				29,455,668
Issuance of common stock Bioniz acquisition		$ 22,542			$ 1			$ 22,541
Issuance of common stock, Bioniz acquisition					4,820,230
Vesting of restricted stock liability	18						18
Stock-based compensation expense	1,298						1,298
Other comprehensive income (loss)	(316)									(316)
Net loss	(37,417)										(37,417)
Balance at Mar. 31, 2022	$ 52,630			$ 3			$ 200,475			$ (454)	$ (147,394)
Balance, Shares at Mar. 31, 2022				34,275,898